Arjuna Capital Has $3.23 Million Position in GSK plc (NYSE:GSK)

Arjuna Capital raised its position in shares of GSK plc (NYSE:GSK) by 144.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 78,934 shares of the pharmaceutical company’s stock after purchasing an additional 46,621 shares during the quarter. Arjuna Capital’s holdings in GSK were worth $3,227,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Eastern Bank acquired a new stake in GSK during the 3rd quarter valued at $26,000. Concord Wealth Partners raised its stake in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in shares of GSK during the 2nd quarter valued at $37,000. Fortitude Family Office LLC purchased a new position in shares of GSK during the 3rd quarter valued at $42,000. Finally, PrairieView Partners LLC purchased a new position in shares of GSK during the 2nd quarter valued at $47,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK traded down $0.45 during trading hours on Wednesday, reaching $35.07. 1,244,370 shares of the company traded hands, compared to its average volume of 4,002,782. The stock’s fifty day moving average is $39.65 and its 200 day moving average is $40.84. The stock has a market cap of $72.68 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 1.39 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK plc has a 1-year low of $34.29 and a 1-year high of $45.92.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.48%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is currently 100.00%.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on GSK. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and lowered their price target for the company from $53.00 to $39.50 in a report on Tuesday. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.